US Stock Insider Trading | Disc Medicine Discloses 5 Insider Transactions on February 17

K-LinePoet · 2026-02-21T16:38:29+00:00

On February 17, 2026, Disc Medicine disclosed multiple insider transactions, including Director Quisel John D selling 13,300 shares. Other executives also engaged in selling transactions. The company focuses on developing new therapies for severe blood diseases and currently has several clinical products.

K-LinePoet

2026-02-21 16:38:29

Abstract generation in progress

On February 17, 2026, Disc Medicine (IRON) disclosed five insider trading transactions. Director Quisel John D sold 13,300 shares on that date.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	Yu Jonathan Yen-Wen	February 17, 2026	Sell	3,231	62.86	$203,100
February 17, 2026	Executive	Khara Rahul	February 17, 2026	Sell	2,853	62.86	$179,300
February 17, 2026	Executive	Stephenson Pamela	February 17, 2026	Sell	5,531	62.86	$347,700
February 17, 2026	Director	Quisel John D	February 17, 2026	Sell	13,300	62.86	$833,800
February 17, 2026	Executive	Savage William Jacob	February 17, 2026	Sell	3,256	62.86	$204,700
January 21, 2026	Executive	Khara Rahul	January 20, 2026	Sell	1,000	69.74	$69,700
January 21, 2026	Executive	Khara Rahul	January 20, 2026	Buy	1,000	13.50	$13,500
January 5, 2026	Executive	Khara Rahul	January 2, 2026	Sell	4,993	78.62	$392,600
January 5, 2026	Executive	Khara Rahul	January 2, 2026	Sell	350	77.67	$27,200
January 5, 2026	Executive	Khara Rahul	January 2, 2026	Sell	1,157	79.27	$91,700

[Company Profile]

Disc Medicine, Inc. was incorporated in Delaware on June 25, 2020. The company is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing new therapies for patients with severe blood disorders. The company has assembled a pipeline of clinical and preclinical candidates aimed at altering fundamental biological pathways related to erythropoiesis and function, particularly heme biosynthesis and iron homeostasis. Its current pipeline includes bitopertin for the treatment of erythropoietic protoporphyria (EPP), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), as well as Diamond-Blackfan anemia (DBA); DISC-0974 for anemia in myelofibrosis (MF) and anemia in chronic kidney disease (CKD); and DISC-3405 (formerly MWTX-003) for polycythemia vera (PV) and other hematologic disorders. Additionally, the company’s preclinical projects include DISC-0998 for anemia related to inflammatory diseases. The company’s approach to candidate development leverages well-understood molecular mechanisms validated in humans. The company believes that each candidate, if approved, could potentially improve the lives of patients with blood disorders.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.